 Lexington, Massachusetts -- Biotechnology company Avaxia Biologics has secured approximately $1.2 million in additional venture capital investment, according to an SEC regulatory filing.
Avaxia says that is developing "oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract."
Investors in the financing were not disclosed.
The company is still seeking approximately $1 million in additional financing, according to the filing. |